nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—Sudden death, cause unknown—Capecitabine—esophageal cancer	0.0393	0.0544	CcSEcCtD
Zuclopenthixol—Glucose tolerance impaired—Cisplatin—esophageal cancer	0.0268	0.0371	CcSEcCtD
Zuclopenthixol—Trismus—Capecitabine—esophageal cancer	0.0159	0.0221	CcSEcCtD
Zuclopenthixol—Pigmentation disorder—Capecitabine—esophageal cancer	0.0159	0.0221	CcSEcCtD
Zuclopenthixol—Hepatitis cholestatic—Capecitabine—esophageal cancer	0.0132	0.0183	CcSEcCtD
Zuclopenthixol—Ileus paralytic—Capecitabine—esophageal cancer	0.0123	0.017	CcSEcCtD
Zuclopenthixol—Sudden death—Capecitabine—esophageal cancer	0.0104	0.0144	CcSEcCtD
Zuclopenthixol—Rhinorrhoea—Cisplatin—esophageal cancer	0.0089	0.0123	CcSEcCtD
Zuclopenthixol—Sudden death—Methotrexate—esophageal cancer	0.00773	0.0107	CcSEcCtD
Zuclopenthixol—Torsade de pointes—Capecitabine—esophageal cancer	0.00758	0.0105	CcSEcCtD
Zuclopenthixol—Pain—Carboplatin—esophageal cancer	0.0075	0.0104	CcSEcCtD
Zuclopenthixol—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00694	0.00962	CcSEcCtD
Zuclopenthixol—Body temperature increased—Carboplatin—esophageal cancer	0.00693	0.00961	CcSEcCtD
Zuclopenthixol—Rhinorrhoea—Capecitabine—esophageal cancer	0.00656	0.00909	CcSEcCtD
Zuclopenthixol—Polyuria—Cisplatin—esophageal cancer	0.00596	0.00826	CcSEcCtD
Zuclopenthixol—Skin discolouration—Capecitabine—esophageal cancer	0.00588	0.00816	CcSEcCtD
Zuclopenthixol—Haemolytic anaemia—Cisplatin—esophageal cancer	0.0058	0.00803	CcSEcCtD
Zuclopenthixol—Nasal congestion—Cisplatin—esophageal cancer	0.00574	0.00796	CcSEcCtD
Zuclopenthixol—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00562	0.00779	CcSEcCtD
Zuclopenthixol—Amnesia—Cisplatin—esophageal cancer	0.00557	0.00772	CcSEcCtD
Zuclopenthixol—Gait disturbance—Capecitabine—esophageal cancer	0.00545	0.00755	CcSEcCtD
Zuclopenthixol—Injection site reaction—Capecitabine—esophageal cancer	0.00528	0.00732	CcSEcCtD
Zuclopenthixol—Urine output increased—Capecitabine—esophageal cancer	0.0048	0.00666	CcSEcCtD
Zuclopenthixol—Breast disorder—Cisplatin—esophageal cancer	0.00473	0.00655	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Cisplatin—esophageal cancer	0.00468	0.00649	CcSEcCtD
Zuclopenthixol—Abnormal vision—Capecitabine—esophageal cancer	0.00463	0.00642	CcSEcCtD
Zuclopenthixol—Speech disorder—Methotrexate—esophageal cancer	0.0046	0.00638	CcSEcCtD
Zuclopenthixol—Sweating increased—Cisplatin—esophageal cancer	0.00441	0.00611	CcSEcCtD
Zuclopenthixol—Polyuria—Capecitabine—esophageal cancer	0.00439	0.00609	CcSEcCtD
Zuclopenthixol—Skin discolouration—Methotrexate—esophageal cancer	0.00438	0.00607	CcSEcCtD
Zuclopenthixol—Vascular purpura—Capecitabine—esophageal cancer	0.00431	0.00598	CcSEcCtD
Zuclopenthixol—Pancytopenia—Cisplatin—esophageal cancer	0.0043	0.00595	CcSEcCtD
Zuclopenthixol—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00427	0.00592	CcSEcCtD
Zuclopenthixol—Libido decreased—Capecitabine—esophageal cancer	0.00416	0.00577	CcSEcCtD
Zuclopenthixol—Hot flush—Capecitabine—esophageal cancer	0.00412	0.00572	CcSEcCtD
Zuclopenthixol—Amnesia—Capecitabine—esophageal cancer	0.00411	0.00569	CcSEcCtD
Zuclopenthixol—Increased appetite—Capecitabine—esophageal cancer	0.00411	0.00569	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Capecitabine—esophageal cancer	0.00409	0.00567	CcSEcCtD
Zuclopenthixol—Thirst—Capecitabine—esophageal cancer	0.00405	0.00562	CcSEcCtD
Zuclopenthixol—Purpura—Capecitabine—esophageal cancer	0.004	0.00555	CcSEcCtD
Zuclopenthixol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00383	0.0053	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00381	0.00529	CcSEcCtD
Zuclopenthixol—Migraine—Capecitabine—esophageal cancer	0.0038	0.00526	CcSEcCtD
Zuclopenthixol—Urinary retention—Capecitabine—esophageal cancer	0.00367	0.00508	CcSEcCtD
Zuclopenthixol—Ataxia—Capecitabine—esophageal cancer	0.00363	0.00503	CcSEcCtD
Zuclopenthixol—Urine output increased—Methotrexate—esophageal cancer	0.00358	0.00496	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Cisplatin—esophageal cancer	0.00358	0.00496	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Capecitabine—esophageal cancer	0.00356	0.00494	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Cisplatin—esophageal cancer	0.00356	0.00493	CcSEcCtD
Zuclopenthixol—Urethral disorder—Cisplatin—esophageal cancer	0.00355	0.00492	CcSEcCtD
Zuclopenthixol—Gynaecomastia—Methotrexate—esophageal cancer	0.00354	0.00491	CcSEcCtD
Zuclopenthixol—Visual impairment—Cisplatin—esophageal cancer	0.00349	0.00484	CcSEcCtD
Zuclopenthixol—Breast disorder—Capecitabine—esophageal cancer	0.00349	0.00483	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Capecitabine—esophageal cancer	0.00345	0.00478	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.0034	0.00472	CcSEcCtD
Zuclopenthixol—Eye disorder—Cisplatin—esophageal cancer	0.00338	0.00469	CcSEcCtD
Zuclopenthixol—Tinnitus—Cisplatin—esophageal cancer	0.00338	0.00468	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Cisplatin—esophageal cancer	0.00336	0.00466	CcSEcCtD
Zuclopenthixol—Polyuria—Methotrexate—esophageal cancer	0.00327	0.00453	CcSEcCtD
Zuclopenthixol—Immune system disorder—Cisplatin—esophageal cancer	0.00327	0.00453	CcSEcCtD
Zuclopenthixol—Sweating increased—Capecitabine—esophageal cancer	0.00325	0.0045	CcSEcCtD
Zuclopenthixol—Arrhythmia—Cisplatin—esophageal cancer	0.00323	0.00448	CcSEcCtD
Zuclopenthixol—Pancytopenia—Capecitabine—esophageal cancer	0.00317	0.00439	CcSEcCtD
Zuclopenthixol—Erythema—Cisplatin—esophageal cancer	0.00315	0.00437	CcSEcCtD
Zuclopenthixol—Malnutrition—Cisplatin—esophageal cancer	0.00315	0.00437	CcSEcCtD
Zuclopenthixol—Dysuria—Capecitabine—esophageal cancer	0.00312	0.00432	CcSEcCtD
Zuclopenthixol—Neutropenia—Capecitabine—esophageal cancer	0.00312	0.00432	CcSEcCtD
Zuclopenthixol—Flatulence—Cisplatin—esophageal cancer	0.00311	0.0043	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00304	0.00422	CcSEcCtD
Zuclopenthixol—Weight increased—Capecitabine—esophageal cancer	0.00303	0.00421	CcSEcCtD
Zuclopenthixol—Weight decreased—Capecitabine—esophageal cancer	0.00302	0.00418	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Capecitabine—esophageal cancer	0.00301	0.00417	CcSEcCtD
Zuclopenthixol—Vision blurred—Cisplatin—esophageal cancer	0.00297	0.00412	CcSEcCtD
Zuclopenthixol—Tremor—Cisplatin—esophageal cancer	0.00295	0.00409	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Cisplatin—esophageal cancer	0.00292	0.00405	CcSEcCtD
Zuclopenthixol—Jaundice—Capecitabine—esophageal cancer	0.0029	0.00402	CcSEcCtD
Zuclopenthixol—Malaise—Cisplatin—esophageal cancer	0.00284	0.00394	CcSEcCtD
Zuclopenthixol—Leukopenia—Cisplatin—esophageal cancer	0.00282	0.00391	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00281	0.0039	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Capecitabine—esophageal cancer	0.00277	0.00385	CcSEcCtD
Zuclopenthixol—Convulsion—Cisplatin—esophageal cancer	0.00273	0.00378	CcSEcCtD
Zuclopenthixol—Ataxia—Methotrexate—esophageal cancer	0.0027	0.00374	CcSEcCtD
Zuclopenthixol—Myalgia—Cisplatin—esophageal cancer	0.00268	0.00372	CcSEcCtD
Zuclopenthixol—Anxiety—Cisplatin—esophageal cancer	0.00267	0.00371	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00266	0.00369	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Methotrexate—esophageal cancer	0.00265	0.00367	CcSEcCtD
Zuclopenthixol—Discomfort—Cisplatin—esophageal cancer	0.00265	0.00367	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Capecitabine—esophageal cancer	0.00264	0.00365	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Capecitabine—esophageal cancer	0.00263	0.00364	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Capecitabine—esophageal cancer	0.00262	0.00363	CcSEcCtD
Zuclopenthixol—Urethral disorder—Capecitabine—esophageal cancer	0.00262	0.00363	CcSEcCtD
Zuclopenthixol—Breast disorder—Methotrexate—esophageal cancer	0.0026	0.0036	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Cisplatin—esophageal cancer	0.00257	0.00357	CcSEcCtD
Zuclopenthixol—Visual impairment—Capecitabine—esophageal cancer	0.00257	0.00356	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Cisplatin—esophageal cancer	0.00252	0.0035	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Cisplatin—esophageal cancer	0.00252	0.00349	CcSEcCtD
Zuclopenthixol—Tachycardia—Cisplatin—esophageal cancer	0.00251	0.00348	CcSEcCtD
Zuclopenthixol—Skin disorder—Cisplatin—esophageal cancer	0.0025	0.00346	CcSEcCtD
Zuclopenthixol—Eye disorder—Capecitabine—esophageal cancer	0.00249	0.00346	CcSEcCtD
Zuclopenthixol—Tinnitus—Capecitabine—esophageal cancer	0.00249	0.00345	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Cisplatin—esophageal cancer	0.00249	0.00345	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Capecitabine—esophageal cancer	0.00248	0.00343	CcSEcCtD
Zuclopenthixol—Flupentixol—ABCB1—esophageal cancer	0.00247	0.154	CrCbGaD
Zuclopenthixol—Eosinophilia—Methotrexate—esophageal cancer	0.00246	0.00341	CcSEcCtD
Zuclopenthixol—Anorexia—Cisplatin—esophageal cancer	0.00245	0.0034	CcSEcCtD
Zuclopenthixol—Angiopathy—Capecitabine—esophageal cancer	0.00242	0.00336	CcSEcCtD
Zuclopenthixol—Immune system disorder—Capecitabine—esophageal cancer	0.00241	0.00334	CcSEcCtD
Zuclopenthixol—Clozapine—CYP1B1—esophageal cancer	0.0024	0.15	CrCbGaD
Zuclopenthixol—Hypotension—Cisplatin—esophageal cancer	0.0024	0.00333	CcSEcCtD
Zuclopenthixol—Arrhythmia—Capecitabine—esophageal cancer	0.00238	0.0033	CcSEcCtD
Zuclopenthixol—Pancytopenia—Methotrexate—esophageal cancer	0.00236	0.00327	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00234	0.00325	CcSEcCtD
Zuclopenthixol—Mental disorder—Capecitabine—esophageal cancer	0.00234	0.00324	CcSEcCtD
Zuclopenthixol—Erythema—Capecitabine—esophageal cancer	0.00232	0.00322	CcSEcCtD
Zuclopenthixol—Malnutrition—Capecitabine—esophageal cancer	0.00232	0.00322	CcSEcCtD
Zuclopenthixol—Dysuria—Methotrexate—esophageal cancer	0.00232	0.00322	CcSEcCtD
Zuclopenthixol—Neutropenia—Methotrexate—esophageal cancer	0.00232	0.00322	CcSEcCtD
Zuclopenthixol—Paraesthesia—Cisplatin—esophageal cancer	0.00231	0.0032	CcSEcCtD
Zuclopenthixol—Dyspnoea—Cisplatin—esophageal cancer	0.00229	0.00318	CcSEcCtD
Zuclopenthixol—Flatulence—Capecitabine—esophageal cancer	0.00229	0.00317	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00229	0.00317	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00227	0.00314	CcSEcCtD
Zuclopenthixol—Decreased appetite—Cisplatin—esophageal cancer	0.00224	0.0031	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00222	0.00308	CcSEcCtD
Zuclopenthixol—Drowsiness—Methotrexate—esophageal cancer	0.00221	0.00307	CcSEcCtD
Zuclopenthixol—Pain—Cisplatin—esophageal cancer	0.0022	0.00305	CcSEcCtD
Zuclopenthixol—Vision blurred—Capecitabine—esophageal cancer	0.00219	0.00303	CcSEcCtD
Zuclopenthixol—Tremor—Capecitabine—esophageal cancer	0.00218	0.00302	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Capecitabine—esophageal cancer	0.00216	0.00299	CcSEcCtD
Zuclopenthixol—Sweating—Methotrexate—esophageal cancer	0.00212	0.00294	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Cisplatin—esophageal cancer	0.00212	0.00294	CcSEcCtD
Zuclopenthixol—Malaise—Capecitabine—esophageal cancer	0.0021	0.0029	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00209	0.0029	CcSEcCtD
Zuclopenthixol—Vertigo—Capecitabine—esophageal cancer	0.00209	0.00289	CcSEcCtD
Zuclopenthixol—Syncope—Capecitabine—esophageal cancer	0.00208	0.00289	CcSEcCtD
Zuclopenthixol—Leukopenia—Capecitabine—esophageal cancer	0.00208	0.00288	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Methotrexate—esophageal cancer	0.00207	0.00286	CcSEcCtD
Zuclopenthixol—Palpitations—Capecitabine—esophageal cancer	0.00205	0.00285	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Capecitabine—esophageal cancer	0.00204	0.00283	CcSEcCtD
Zuclopenthixol—Body temperature increased—Cisplatin—esophageal cancer	0.00203	0.00282	CcSEcCtD
Zuclopenthixol—Hypertension—Capecitabine—esophageal cancer	0.00201	0.00278	CcSEcCtD
Zuclopenthixol—Myalgia—Capecitabine—esophageal cancer	0.00198	0.00274	CcSEcCtD
Zuclopenthixol—Anxiety—Capecitabine—esophageal cancer	0.00197	0.00273	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00196	0.00272	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Methotrexate—esophageal cancer	0.00196	0.00272	CcSEcCtD
Zuclopenthixol—Discomfort—Capecitabine—esophageal cancer	0.00195	0.00271	CcSEcCtD
Zuclopenthixol—Urethral disorder—Methotrexate—esophageal cancer	0.00195	0.0027	CcSEcCtD
Zuclopenthixol—Dry mouth—Capecitabine—esophageal cancer	0.00193	0.00268	CcSEcCtD
Zuclopenthixol—Visual impairment—Methotrexate—esophageal cancer	0.00191	0.00265	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Cisplatin—esophageal cancer	0.0019	0.00263	CcSEcCtD
Zuclopenthixol—Shock—Capecitabine—esophageal cancer	0.00187	0.00259	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Capecitabine—esophageal cancer	0.00186	0.00258	CcSEcCtD
Zuclopenthixol—Eye disorder—Methotrexate—esophageal cancer	0.00186	0.00257	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Capecitabine—esophageal cancer	0.00186	0.00257	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2A6—esophageal cancer	0.00185	0.116	CrCbGaD
Zuclopenthixol—Tinnitus—Methotrexate—esophageal cancer	0.00185	0.00257	CcSEcCtD
Zuclopenthixol—Tachycardia—Capecitabine—esophageal cancer	0.00185	0.00256	CcSEcCtD
Zuclopenthixol—Asthenia—Cisplatin—esophageal cancer	0.00185	0.00256	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Methotrexate—esophageal cancer	0.00184	0.00256	CcSEcCtD
Zuclopenthixol—Skin disorder—Capecitabine—esophageal cancer	0.00184	0.00255	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Capecitabine—esophageal cancer	0.00183	0.00254	CcSEcCtD
Zuclopenthixol—Anorexia—Capecitabine—esophageal cancer	0.00181	0.00251	CcSEcCtD
Zuclopenthixol—Angiopathy—Methotrexate—esophageal cancer	0.0018	0.0025	CcSEcCtD
Zuclopenthixol—Immune system disorder—Methotrexate—esophageal cancer	0.00179	0.00249	CcSEcCtD
Zuclopenthixol—Hypotension—Capecitabine—esophageal cancer	0.00177	0.00246	CcSEcCtD
Zuclopenthixol—Diarrhoea—Cisplatin—esophageal cancer	0.00176	0.00244	CcSEcCtD
Zuclopenthixol—Mental disorder—Methotrexate—esophageal cancer	0.00174	0.00241	CcSEcCtD
Zuclopenthixol—Malnutrition—Methotrexate—esophageal cancer	0.00173	0.0024	CcSEcCtD
Zuclopenthixol—Erythema—Methotrexate—esophageal cancer	0.00173	0.0024	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00173	0.00239	CcSEcCtD
Zuclopenthixol—Insomnia—Capecitabine—esophageal cancer	0.00171	0.00238	CcSEcCtD
Zuclopenthixol—Paraesthesia—Capecitabine—esophageal cancer	0.0017	0.00236	CcSEcCtD
Zuclopenthixol—Dyspnoea—Capecitabine—esophageal cancer	0.00169	0.00234	CcSEcCtD
Zuclopenthixol—Dyspepsia—Capecitabine—esophageal cancer	0.00167	0.00231	CcSEcCtD
Zuclopenthixol—Domperidone—ABCB1—esophageal cancer	0.00166	0.104	CrCbGaD
Zuclopenthixol—Decreased appetite—Capecitabine—esophageal cancer	0.00165	0.00228	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00164	0.00227	CcSEcCtD
Zuclopenthixol—Vomiting—Cisplatin—esophageal cancer	0.00164	0.00227	CcSEcCtD
Zuclopenthixol—Fatigue—Capecitabine—esophageal cancer	0.00163	0.00227	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—esophageal cancer	0.00163	0.00226	CcSEcCtD
Zuclopenthixol—Rash—Cisplatin—esophageal cancer	0.00162	0.00225	CcSEcCtD
Zuclopenthixol—Constipation—Capecitabine—esophageal cancer	0.00162	0.00225	CcSEcCtD
Zuclopenthixol—Pain—Capecitabine—esophageal cancer	0.00162	0.00225	CcSEcCtD
Zuclopenthixol—Dermatitis—Cisplatin—esophageal cancer	0.00162	0.00225	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—esophageal cancer	0.0016	0.00222	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Capecitabine—esophageal cancer	0.00156	0.00217	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—esophageal cancer	0.00156	0.00216	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—esophageal cancer	0.00155	0.00215	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00155	0.00215	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—esophageal cancer	0.00155	0.00215	CcSEcCtD
Zuclopenthixol—Nausea—Cisplatin—esophageal cancer	0.00153	0.00212	CcSEcCtD
Zuclopenthixol—Body temperature increased—Capecitabine—esophageal cancer	0.0015	0.00208	CcSEcCtD
Zuclopenthixol—Abdominal pain—Capecitabine—esophageal cancer	0.0015	0.00208	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—esophageal cancer	0.0015	0.00208	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—esophageal cancer	0.00147	0.00204	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00146	0.00203	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—esophageal cancer	0.00145	0.00202	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—esophageal cancer	0.00141	0.00196	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Capecitabine—esophageal cancer	0.0014	0.00194	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—esophageal cancer	0.00138	0.00192	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—esophageal cancer	0.00138	0.00192	CcSEcCtD
Zuclopenthixol—Nefazodone—ABCB1—esophageal cancer	0.00138	0.0863	CrCbGaD
Zuclopenthixol—Skin disorder—Methotrexate—esophageal cancer	0.00137	0.0019	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—esophageal cancer	0.00136	0.00189	CcSEcCtD
Zuclopenthixol—Asthenia—Capecitabine—esophageal cancer	0.00136	0.00189	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—esophageal cancer	0.00135	0.00186	CcSEcCtD
Zuclopenthixol—Pruritus—Capecitabine—esophageal cancer	0.00134	0.00186	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—esophageal cancer	0.00132	0.00183	CcSEcCtD
Zuclopenthixol—Diarrhoea—Capecitabine—esophageal cancer	0.0013	0.0018	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00129	0.00178	CcSEcCtD
Zuclopenthixol—Trazodone—ABCB1—esophageal cancer	0.00128	0.0799	CrCbGaD
Zuclopenthixol—Insomnia—Methotrexate—esophageal cancer	0.00128	0.00177	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—esophageal cancer	0.00127	0.00176	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—esophageal cancer	0.00126	0.00174	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—esophageal cancer	0.00125	0.00174	CcSEcCtD
Zuclopenthixol—Dizziness—Capecitabine—esophageal cancer	0.00125	0.00174	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—esophageal cancer	0.00124	0.00172	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—esophageal cancer	0.00123	0.0017	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00122	0.00169	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—esophageal cancer	0.00122	0.00169	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—esophageal cancer	0.00121	0.00167	CcSEcCtD
Zuclopenthixol—Vomiting—Capecitabine—esophageal cancer	0.00121	0.00167	CcSEcCtD
Zuclopenthixol—Rash—Capecitabine—esophageal cancer	0.0012	0.00166	CcSEcCtD
Zuclopenthixol—Dermatitis—Capecitabine—esophageal cancer	0.00119	0.00166	CcSEcCtD
Zuclopenthixol—Headache—Capecitabine—esophageal cancer	0.00119	0.00165	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—esophageal cancer	0.00116	0.00161	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00115	0.0016	CcSEcCtD
Zuclopenthixol—Nausea—Capecitabine—esophageal cancer	0.00113	0.00156	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—esophageal cancer	0.00112	0.00155	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—esophageal cancer	0.00112	0.00155	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—esophageal cancer	0.00104	0.00144	CcSEcCtD
Zuclopenthixol—Fluphenazine—ABCB1—esophageal cancer	0.00103	0.0647	CrCbGaD
Zuclopenthixol—Asthenia—Methotrexate—esophageal cancer	0.00101	0.0014	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—esophageal cancer	0.000999	0.00138	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—esophageal cancer	0.000966	0.00134	CcSEcCtD
Zuclopenthixol—Chlorprothixene—ABCB1—esophageal cancer	0.000942	0.0589	CrCbGaD
Zuclopenthixol—Dizziness—Methotrexate—esophageal cancer	0.000933	0.00129	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—esophageal cancer	0.000897	0.00124	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—esophageal cancer	0.00089	0.00123	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—esophageal cancer	0.000889	0.00123	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—esophageal cancer	0.000884	0.00123	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—esophageal cancer	0.000838	0.00116	CcSEcCtD
Zuclopenthixol—Trifluoperazine—ABCB1—esophageal cancer	0.000827	0.0517	CrCbGaD
Zuclopenthixol—Quetiapine—ABCB1—esophageal cancer	0.000802	0.0501	CrCbGaD
Zuclopenthixol—Clozapine—ABCB1—esophageal cancer	0.00069	0.0431	CrCbGaD
Zuclopenthixol—Chlorpromazine—ABCB1—esophageal cancer	0.000649	0.0406	CrCbGaD
Zuclopenthixol—DRD2—Signaling Pathways—GNG7—esophageal cancer	0.000123	0.000467	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GNG7—esophageal cancer	0.000121	0.00046	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GNG7—esophageal cancer	0.00012	0.000459	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GNG7—esophageal cancer	0.000118	0.00045	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GSTT1—esophageal cancer	0.000117	0.000446	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HIF1A—esophageal cancer	0.000117	0.000446	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFBR2—esophageal cancer	0.000117	0.000444	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000117	0.000444	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP2A6—esophageal cancer	0.000116	0.000441	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	0.000115	0.00044	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—XIAP—esophageal cancer	0.000115	0.000438	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000114	0.000434	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—NOS3—esophageal cancer	0.000113	0.000432	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NOTCH2—esophageal cancer	0.000113	0.000431	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—XIAP—esophageal cancer	0.000113	0.000431	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—XIAP—esophageal cancer	0.000113	0.00043	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KDR—esophageal cancer	0.000112	0.000426	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—XIAP—esophageal cancer	0.000111	0.000422	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SMAD4—esophageal cancer	0.00011	0.000421	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	0.00011	0.000418	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS1—esophageal cancer	0.00011	0.000418	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ENO1—esophageal cancer	0.00011	0.000418	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000109	0.000414	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CTNNA1—esophageal cancer	0.000109	0.000414	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PSME2—esophageal cancer	0.000108	0.000412	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PSME1—esophageal cancer	0.000108	0.000412	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL2—esophageal cancer	0.000108	0.000412	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CTNNA1—esophageal cancer	0.000107	0.000408	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CTNNA1—esophageal cancer	0.000107	0.000407	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL2—esophageal cancer	0.000106	0.000405	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL2—esophageal cancer	0.000106	0.000404	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000106	0.000403	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NOTCH1—esophageal cancer	0.000105	0.000402	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000105	0.000399	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	0.000104	0.000397	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000103	0.000393	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	0.000103	0.000392	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PSME2—esophageal cancer	0.000101	0.000385	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PSME1—esophageal cancer	0.000101	0.000385	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ANXA1—esophageal cancer	0.000101	0.000383	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFBR2—esophageal cancer	0.0001	0.000382	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PSME2—esophageal cancer	9.94e-05	0.000379	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PSME1—esophageal cancer	9.94e-05	0.000379	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PSME2—esophageal cancer	9.92e-05	0.000378	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PSME1—esophageal cancer	9.92e-05	0.000378	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	9.89e-05	0.000377	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ANXA1—esophageal cancer	9.87e-05	0.000376	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TPI1—esophageal cancer	9.84e-05	0.000375	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTO1—esophageal cancer	9.84e-05	0.000375	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SST—esophageal cancer	9.78e-05	0.000372	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	9.73e-05	0.000371	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	9.73e-05	0.000371	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	9.73e-05	0.000371	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	9.68e-05	0.000369	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	9.68e-05	0.000369	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SST—esophageal cancer	9.62e-05	0.000366	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SST—esophageal cancer	9.6e-05	0.000366	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CREBBP—esophageal cancer	9.56e-05	0.000364	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GHRL—esophageal cancer	9.53e-05	0.000363	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOTCH3—esophageal cancer	9.53e-05	0.000363	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SMAD4—esophageal cancer	9.51e-05	0.000362	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALDOB—esophageal cancer	9.43e-05	0.000359	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SST—esophageal cancer	9.42e-05	0.000359	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—EGFR—esophageal cancer	9.4e-05	0.000358	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GHRL—esophageal cancer	9.38e-05	0.000357	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	9.38e-05	0.000357	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FBXW7—esophageal cancer	9.37e-05	0.000357	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOTCH3—esophageal cancer	9.36e-05	0.000356	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GHRL—esophageal cancer	9.36e-05	0.000356	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP1B1—esophageal cancer	9.33e-05	0.000355	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	9.22e-05	0.000351	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FBXW7—esophageal cancer	9.2e-05	0.000351	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	9.18e-05	0.00035	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	9.18e-05	0.00035	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GAPDH—esophageal cancer	9.08e-05	0.000346	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	9.04e-05	0.000344	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	9.04e-05	0.000344	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HIF1A—esophageal cancer	9.04e-05	0.000344	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	9.03e-05	0.000344	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CRABP1—esophageal cancer	9e-05	0.000343	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	9e-05	0.000343	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—PIK3CA—esophageal cancer	8.98e-05	0.000342	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP19A1—esophageal cancer	8.77e-05	0.000334	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SST—esophageal cancer	8.75e-05	0.000333	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KDR—esophageal cancer	8.64e-05	0.000329	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—EP300—esophageal cancer	8.63e-05	0.000329	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GNG7—esophageal cancer	8.56e-05	0.000326	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NOS3—esophageal cancer	8.56e-05	0.000326	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	8.55e-05	0.000326	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	8.53e-05	0.000325	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	8.53e-05	0.000325	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	8.41e-05	0.00032	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	8.39e-05	0.00032	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	8.39e-05	0.00032	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	8.23e-05	0.000314	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—PIK3CA—esophageal cancer	8.15e-05	0.000311	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NOTCH1—esophageal cancer	8.14e-05	0.00031	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALDH2—esophageal cancer	8.02e-05	0.000306	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—ERBB2—esophageal cancer	8.01e-05	0.000305	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—HMOX1—esophageal cancer	8e-05	0.000305	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HIF1A—esophageal cancer	7.78e-05	0.000296	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ABCB1—esophageal cancer	7.68e-05	0.000293	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	7.65e-05	0.000291	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.63e-05	0.000291	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	7.58e-05	0.000289	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.54e-05	0.000287	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	7.46e-05	0.000284	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	7.44e-05	0.000284	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KDR—esophageal cancer	7.44e-05	0.000283	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CREBBP—esophageal cancer	7.38e-05	0.000281	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	7.3e-05	0.000278	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—EGFR—esophageal cancer	7.25e-05	0.000276	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SMAD4—esophageal cancer	7.18e-05	0.000273	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS1—esophageal cancer	7.15e-05	0.000272	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ENO1—esophageal cancer	7.15e-05	0.000272	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CCND1—esophageal cancer	7.07e-05	0.000269	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	7.06e-05	0.000269	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SMAD4—esophageal cancer	7.05e-05	0.000268	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PSME2—esophageal cancer	7.05e-05	0.000268	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PSME1—esophageal cancer	7.05e-05	0.000268	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NOTCH1—esophageal cancer	7.01e-05	0.000267	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—PIK3CA—esophageal cancer	6.93e-05	0.000264	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	6.91e-05	0.000263	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—CDKN1A—esophageal cancer	6.84e-05	0.000261	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	6.79e-05	0.000259	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NOS3—esophageal cancer	6.61e-05	0.000252	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—EP300—esophageal cancer	6.51e-05	0.000248	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	6.42e-05	0.000245	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	6.38e-05	0.000243	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CREBBP—esophageal cancer	6.35e-05	0.000242	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—PIK3CA—esophageal cancer	6.29e-05	0.00024	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—EGFR—esophageal cancer	6.24e-05	0.000238	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—ERBB2—esophageal cancer	6.18e-05	0.000235	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—TP53—esophageal cancer	6.17e-05	0.000235	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	6.08e-05	0.000232	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	5.97e-05	0.000227	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HIF1A—esophageal cancer	5.87e-05	0.000224	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	5.78e-05	0.00022	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HIF1A—esophageal cancer	5.77e-05	0.00022	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.72e-05	0.000218	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NOS3—esophageal cancer	5.69e-05	0.000217	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MYC—esophageal cancer	5.67e-05	0.000216	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	5.66e-05	0.000215	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KDR—esophageal cancer	5.62e-05	0.000214	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—EGFR—esophageal cancer	5.55e-05	0.000211	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KDR—esophageal cancer	5.53e-05	0.00021	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KDR—esophageal cancer	5.51e-05	0.00021	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CCND1—esophageal cancer	5.46e-05	0.000208	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	5.42e-05	0.000206	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KDR—esophageal cancer	5.41e-05	0.000206	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ERBB2—esophageal cancer	5.32e-05	0.000203	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	5.29e-05	0.000202	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CDKN1A—esophageal cancer	5.28e-05	0.000201	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	5.26e-05	0.0002	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.22e-05	0.000199	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	5.21e-05	0.000198	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	5.19e-05	0.000198	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CREBBP—esophageal cancer	5.13e-05	0.000196	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	5.1e-05	0.000194	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KDR—esophageal cancer	5.03e-05	0.000191	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EP300—esophageal cancer	5.03e-05	0.000191	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.01e-05	0.000191	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—PIK3CA—esophageal cancer	4.82e-05	0.000183	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CREBBP—esophageal cancer	4.8e-05	0.000183	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	4.74e-05	0.00018	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	4.72e-05	0.00018	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—EGFR—esophageal cancer	4.71e-05	0.00018	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CREBBP—esophageal cancer	4.71e-05	0.000179	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—esophageal cancer	4.7e-05	0.000179	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—esophageal cancer	4.66e-05	0.000178	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	4.64e-05	0.000177	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—esophageal cancer	4.63e-05	0.000176	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	4.62e-05	0.000176	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NOS3—esophageal cancer	4.6e-05	0.000175	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	4.55e-05	0.000173	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	4.54e-05	0.000173	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	4.5e-05	0.000172	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.43e-05	0.000169	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	4.42e-05	0.000168	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—esophageal cancer	4.38e-05	0.000167	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.34e-05	0.000165	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EP300—esophageal cancer	4.33e-05	0.000165	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOS3—esophageal cancer	4.29e-05	0.000164	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	4.29e-05	0.000164	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—esophageal cancer	4.28e-05	0.000163	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOS3—esophageal cancer	4.23e-05	0.000161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	4.22e-05	0.000161	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOS3—esophageal cancer	4.22e-05	0.000161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—esophageal cancer	4.2e-05	0.00016	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	4.14e-05	0.000158	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	4.09e-05	0.000156	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.03e-05	0.000154	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	4.03e-05	0.000153	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ERBB2—esophageal cancer	4.02e-05	0.000153	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	4.02e-05	0.000153	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	3.95e-05	0.000151	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ERBB2—esophageal cancer	3.94e-05	0.00015	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	3.94e-05	0.00015	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	3.87e-05	0.000147	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	3.84e-05	0.000146	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—esophageal cancer	3.77e-05	0.000144	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	3.72e-05	0.000142	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—esophageal cancer	3.69e-05	0.00014	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.66e-05	0.000139	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—esophageal cancer	3.6e-05	0.000137	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	3.6e-05	0.000137	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—esophageal cancer	3.55e-05	0.000135	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—EP300—esophageal cancer	3.5e-05	0.000133	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—esophageal cancer	3.49e-05	0.000133	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—esophageal cancer	3.48e-05	0.000133	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	3.43e-05	0.000131	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	3.42e-05	0.00013	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	3.38e-05	0.000129	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	3.37e-05	0.000128	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.35e-05	0.000127	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	3.31e-05	0.000126	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EP300—esophageal cancer	3.27e-05	0.000124	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EP300—esophageal cancer	3.21e-05	0.000122	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EP300—esophageal cancer	3.21e-05	0.000122	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	3.2e-05	0.000122	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	3.18e-05	0.000121	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EP300—esophageal cancer	3.15e-05	0.00012	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—esophageal cancer	3.1e-05	0.000118	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	3.07e-05	0.000117	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NOS3—esophageal cancer	3e-05	0.000114	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2.92e-05	0.000111	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—esophageal cancer	2.85e-05	0.000108	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—esophageal cancer	2.8e-05	0.000107	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—esophageal cancer	2.79e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—esophageal cancer	2.78e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—esophageal cancer	2.74e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.74e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—esophageal cancer	2.74e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—esophageal cancer	2.73e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	2.68e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—esophageal cancer	2.59e-05	9.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—esophageal cancer	2.55e-05	9.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	2.49e-05	9.49e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	2.42e-05	9.2e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	2.38e-05	9.06e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	2.37e-05	9.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—esophageal cancer	2.34e-05	8.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	2.33e-05	8.87e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—esophageal cancer	2.3e-05	8.76e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—esophageal cancer	2.3e-05	8.74e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—EP300—esophageal cancer	2.28e-05	8.68e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—esophageal cancer	2.25e-05	8.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	2.16e-05	8.24e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—esophageal cancer	2.09e-05	7.97e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.69e-05	6.42e-05	CbGpPWpGaD
